Adhd -

ADHD, executive function, dopamine, methylphenidate, neurodevelopment, adult ADHD, comorbidity 1. Introduction Attention-Deficit/Hyperactivity Disorder (ADHD) has transitioned from a controversial diagnosis of disruptive boys to a well-validated neurobiological condition with persistent effects across the lifespan. First formally described by Sir George Still in 1902 as a "defect in moral control," the disorder was officially recognized in DSM-II (1968) as "Hyperkinetic Reaction of Childhood." The current DSM-5-TR (2022) defines ADHD by persistent patterns of inattention, hyperactivity, and impulsivity that are developmentally inappropriate, impair functioning, and present before age 12.

Longitudinal studies (e.g., the Multimodal Treatment Study of ADHD – MTA) show that while overt hyperactivity declines with age, inattention and executive dysfunction often persist. Approximately 60% of childhood cases meet full criteria in adulthood, with another 25% exhibiting residual impairment (subthreshold symptoms). Early-onset, severe hyperactivity, and co-occurring conduct problems predict persistence. Longitudinal studies (e

Up to 20% of college students without ADHD report nonmedical stimulant use (primarily for cognitive enhancement). Long-term effects of chronic misuse include cardiovascular risk and potential for psychosis at high doses. Up to 20% of college students without ADHD

The shift from a categorical to a more dimensional understanding has been driven by neuroimaging, genetics, and treatment response studies. This paper argues that ADHD is best understood as a disorder of functional connectivity in large-scale brain networks, particularly the default mode network (DMN) and the central executive network (CEN). The review proceeds as follows: Section 2 covers epidemiology and developmental trajectories; Section 3 details neurobiological mechanisms; Section 4 examines diagnostic criteria and pitfalls; Section 5 reviews evidence-based treatments; Section 6 explores adult outcomes; Section 7 discusses controversies and future directions. Prevalence: Meta-analyses (Polanczyk et al., 2014; 2023 update) estimate global prevalence at 5.9% in children/adolescents and 2.5% in adults. Rates vary by diagnostic method: teacher ratings yield higher estimates (~7-10%) than structured clinical interviews (~5%). Sex ratios are approximately 3:1 (male:female) in childhood, narrowing to 2:1 by adulthood as female-predominant inattentive presentations become more recognized. Whether this represents late-onset ADHD

Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most prevalent neurodevelopmental disorders, affecting approximately 5-7% of children and 2.5% of adults worldwide. Once viewed as a childhood-limited condition characterized by hyperactivity and inattention, contemporary research frames ADHD as a lifelong, heterogeneous disorder of executive function, reward processing, and temporal processing. This paper synthesizes current findings on the genetic and neurobiological underpinnings—highlighting dopaminergic and noradrenergic dysregulation in fronto-striatal-cerebellar circuits. It critically evaluates diagnostic challenges, including sex-based phenotypic differences and high comorbidity with autism spectrum disorder (ASD), anxiety, and oppositional defiant disorder (ODD). Evidence-based interventions are reviewed: stimulant pharmacotherapy (methylphenidate, amphetamines), non-stimulants (atomoxetine, guanfacine), and behavioral therapies. Finally, the paper addresses the emerging adult ADHD phenotype, including risks for occupational instability, substance use, and accidental injury, while advocating for lifespan, multimodal management.

DSM-5 requires onset before age 12, but longitudinal studies (e.g., the Dunedin cohort) identify a small group (~5-10% of adult ADHD cases) with first symptoms emerging in adulthood without childhood history. Whether this represents late-onset ADHD, a distinct disorder, or misattribution of symptoms to other conditions remains debated.